argyrotsipi/train-dataset huggingface dataset:
Local Libraries and Regional Museums — House of Commons, 2022-03-24
Topic: Culture
Kevin Denis Brennan (Labour, Centre-left): Libraries are cultural institutions that are perhaps most accessible to a lot of the people we talk about wanting to help, who will often go into a library more easily than they might to a museum or theatre. Local authorities have a statutory obligation to provide a comprehensive service. What steps will the Minister take to ensure that local authorities are meeting that obligation and that our libraries continue to be able to offer access to all parts of our communities?
Local Libraries and Regional Museums — House of Commons, 2022-03-24
Topic: Culture
Barry John Sheerman (Labour, Centre-left): I declare an interest, as chair of the John Clare Trust, in the English poet’s house in Helpston near Peterborough and Stamford. Will the Minister do something for me and give the National Trust a good shaking? So often, the small literary houses and smaller places get neglected. The National Trust, with all its vast reserves, is obsessed with the great mansions of the rich and the powerful from the past. When will these little museums get the extra help that they need?
Local Libraries and Regional Museums — House of Commons, 2022-03-24
Topic: Culture
Andrew John Gwynne (Labour, Centre-left): Regional museums are great, but let us not forget about local museums. From Tameside’s Portland Basin Museum to Stockport’s Hat Works Museum, they tell the story of who we are. However, research from the Museums Association shows that there has been a 27% decline in spending on local museums by local government since 2010. What is the Minister’s Department doing to ensure that councils invest in local museums so that we can continue to tell the story of our local communities?
Breast Cancer Drugs — House of Commons, 2017-01-26
Topic: Health
Iain Aitken Stewart (Conservative, Centre-right): That sounds an eminently sensible suggestion. As I say, I do not pretend to be an expert on the system, but, surely, something like that could be done. Then the money saved could be added to the cancer drugs fund and make more drugs such as Kadcyla available to people who need them I will end my comments, as I know there are many Members who want to contribute. Please let us try to do everything we can in this House to encourage NICE and Roche to look at the overall system and to look in particular at this drug. It means so much to my constituent and to many others up and down the country. I hope that this debate has that effect. I conclude where I started, by congratulating the hon. Member for Mitcham and Morden on securing it.
Breast Cancer Drugs — House of Commons, 2017-01-26
Topic: Health
Felicia Jane Beatrix Drummond (Conservative, Centre-right): It is a pleasure to speak in the debate, and I congratulate the hon. Member for Mitcham and Morden (Siobhain McDonagh) on securing it. I was really honoured to be able to back the application to the Backbench Business Committee. I also thank her for her powerful speech, which was very moving Fighting cancer is not just a top priority for the NHS but one of the great scientific challenges of our time. Treating our illnesses with science rather than superstition is a relatively new idea in the history of medicine. However, the acceleration of better diagnosis, better treatment and more successful outcomes is keeping more of us alive for longer, and with a better quality of life The motion mentions Kadcyla, a treatment that NICE is not currently able to recommend for the treatment of secondary breast cancer, and we await the result of its consultation in March. This treatment is a relative of another medicine, which, in its introduction, was also extremely controversial—Herceptin. After a lot of consideration by NICE and a lot of debate and pressure from this House, Herceptin was approved. It has helped thousands of people—men get breast cancer too—in fighting breast cancer. Kadcyla is a treatment that could help women who have already been on an Herceptin-based treatment and whose cancer has continued to advance. We must be clear when we talk about secondary, or metastatic, cancer that we are talking about people whose lives will be massively shortened by cancer. Kadcyla gives them and their families more time and a better quality of life. It can add months to the life expectancy of patients whose remaining lives are likely to be measured in only a few months. The hon. Lady movingly talked about some of her friends and some of those in the Public Gallery I think we all understand that there are ultimate financial constraints on the NHS, even though spending on it has increased. I really welcome the new cancer drugs fund, which provides patients with much better access to the most promising new cancer treatments, while providing value for the taxpayer.
Breast Cancer Drugs — House of Commons, 2017-01-26
Topic: Health
Theresa Anne Villiers (Conservative, Centre-right): I was profoundly moved by the case of my constituent, Rosalie Marshall, who sadly is suffering from breast cancer. She told me that she finds it hard to understand why the NHS can spend such significant sums on conditions which, frankly, are not life-threatening and sometimes seem to verge on the cosmetic, and yet not give priority to vital drugs like Kadcyla. Surely something is wrong, and savings could be made in other parts of the NHS that would more than pay for Kadcyla.
Breast Cancer Drugs — House of Commons, 2017-01-26
Topic: Health
Steven John Baker (Conservative, Centre-right): I congratulate the hon. Member for Mitcham and Morden (Siobhain McDonagh) on securing the debate. Like other hon. Members, I am here today to represent my constituents’ concerns. I should say from the off that I join the cause to make Kadcyla more available. When my staff and I were discussing the correspondence about the debate and particular constituency cases, we quickly agreed that this is the worst sort of correspondence that we receive—when people are terminally ill but unable to access the medicines that they need. The subject is particularly acute—I do not think that I am the first Member to struggle to keep a quaver out of my voice—because my mother-in-law died of secondary cancer. These things will stay with us all. None of us can know what ladies who are currently suffering from these diseases are going through, but when we have seen it at second hand, we all want to live in a world where the NHS does not have to practise any rationing I want to focus on that point because, as the hon. Member for Coventry South (Mr Cunningham) said, the problem is intractable. I know about some of the great difficulties in bringing forward Abiraterone to help men, in a similar set of circumstances, suffering from prostate cancer. In a sense, I sympathise with the Minister and with NICE because they have an extremely difficult task. While it is easy for all of us to say that of course Kadcyla should be freely available to all those who need it without restriction, I am well aware that the problem is long-standing and applies to many innovative pharmaceuticals I also appreciate that it is no comfort whatever to sufferers of various cancers to know that a profit-making pharmaceutical system has a far better record of innovation than the alternative planned systems. I wish the Minister every success in her crucial task of working out how to ensure that innovative medicines come forward at a lower cost and a greater rate.
Breast Cancer Drugs — House of Commons, 2017-01-26
Topic: Health
Steven John Baker (Conservative, Centre-right): I have listened carefully to the hon. Gentleman, and of course he raises a perfectly reasonable concern, but the campaign director of Vote Leave had, as one of his particular bugbears, the costs associated with the clinical trials directive and its prejudicial effect on innovation in medicines. I hope that the Government can find a better way through than the previous system and that, in leaving the EU, we will not only solve the problem of the EMA but have a better regulatory system afterwards.
Breast Cancer Drugs — House of Commons, 2017-01-26
Topic: Health
Iain Aitken Stewart (Conservative, Centre-right): The hon. Lady has made a powerful point. In the case of the most aggressive cancers, the period between diagnosis and death can be very short. As she says, any extension of life enabling women to celebrate family events, or anything else, is incredibly important, and we should not lose sight of that.
Breast Cancer Drugs — House of Commons, 2017-01-26
Topic: Health
Nicola Blackwood (Conservative, Centre-right): A large number of important and technical points have been raised today, and I will do my best to respond to as many of them as possible, but where I am unable to do so, I hope that colleagues will allow me to write to them. I congratulate the hon. Member for Mitcham and Morden (Siobhain McDonagh) on securing this important debate, and I join Members across the House in paying tribute to the all-party parliamentary group on breast cancer for all its advocacy on behalf of patients and families. The hon. Lady has campaigned tirelessly to improve access to breast cancer drugs on behalf of her constituents, and I share her commitment to ensuring that patients are able to benefit from the latest effective and often cutting-edge cancer drugs and technologies Cancer is a truly terrible disease, and as has been made clear by the many moving personal contributions that we have heard today, there are few of us who have not been touched by it. That is why the availability of effective drugs to treat cancer is of such importance to all of us and to so many of our constituents. I particularly want to thank all those who have allowed their personal stories to be shared today, and all who are here in the Public Gallery. These stories remind us powerfully of why we are all here, and their importance cannot be overestimated.
Breast Cancer Drugs — House of Commons, 2017-01-26
Topic: Health
Desmond Angus Swayne (Conservative, Centre-right): There is an all-party group for almost every disease known to man, with the possible exception of rigor mortis. If patients and campaigners are to have confidence in clinical decision makers, there will have to be profound changes. At the moment, people lobby their MPs, who are uniquely unqualified to make these decisions. May I suggest to my hon. Friend that one of the changes might need to involve a thorough review of the framework and guidance under which the National Institute for Health and Care Excellence operates?
Northern Ireland Assembly Election — House of Commons, 2017-01-17
Topic: Defense
James Peter Brokenshire (Conservative, Centre-right): My hon. Friend raises the important issue of legacy. As I indicated to the House last week, I will never tire of praising the work of our armed forces personnel in securing the peace, the stability and the arrangements that we see in Northern Ireland today. Yes, I do have some concerns about imbalance within the system, which is why I believe it is right that we move forward with the Stormont House agreement and the legacy bodies that are set up there. I will not comment on any individual decisions. Indeed, justice is devolved in Northern Ireland. It is independent, and has its own processes that remain in place in an independent way. I hear clearly his very general and very firm point on balance within the overall system, which is something that I am very keen to address.
Northern Ireland Assembly Election — House of Commons, 2017-01-17
Topic: Health
James Peter Brokenshire (Conservative, Centre-right): Clearly, RHI scheme issues have been very much at the heart of what has led to the election that I have now called. It is right that we get answers on that, because it is crucial to re-establishing trust and confidence, seeing accountability and giving answers to the public about what has taken place. As I have said, it is right for that to come from Northern Ireland, as much as is possible, as this was a devolved issue and something that related to decisions within Northern Ireland. But I stand ready to work with people and consider options on a cross-community basis where support is commanded across the community. This is about how we get those answers and inject confidence back into the whole process.
Northern Ireland Assembly Election — House of Commons, 2017-01-17
Topic: Defense
James Peter Brokenshire (Conservative, Centre-right): On the issue of legacy, the Stormont House agreement, to which all the parties signed up, provided the right framework and the right way forward. I hold stark national security responsibilities that I feel very keenly about, in terms of safety on the streets of Northern Ireland here and now, and what that means more broadly. On the issue of legacy, it is important that we are able to find a way forward that is more balanced and proportionate, and that sees Northern Ireland looking to the future, rather than the past. We must focus on providing that framework, so that we can move things forward in that way. The hon. Gentleman will well know the issues and bodies set out previously, and, indeed, the way in which engagement has taken place over many months. I believe there is a way forward, but we need to have the framework, the intent, and the balanced and proportionate approach that I continue to underline.
Shared Rural Network — House of Lords, 2019-10-28
Topic: Defense
Diana Barran (Conservative, Centre-right): I thank my noble friend for her question. She describes the North York Moors as "super sparse"; I would say they were super beautiful when I was last there. On using the emergency services infrastructure, I will write to my noble friend if my understanding is incorrect, but where she is absolutely right is that the priority in terms of the use of emergency services infrastructure is for emergency services personnel. Nothing we are planning should interrupt that and there should be no disruption to the emergency services network as a result of this proposal, but we believe that, where it is possible and appropriate, that infrastructure should be made available to share with commercial operators to deliver the coverage improvements that are needed.
Restoration and Renewal — House of Commons, 2017-02-02
Topic: Health
Questions: What plans he has for the House to debate and vote on the timetable and budget for the restoration and renewal of the Palace of Westminster; and if he will make a statement.
Michael Tyrone Ellis (Conservative, Centre-right): I recommend any Member of the House who has not read the report to read it, because it particularises in fine detail some of the concerns that the hon. Gentleman mentions about health and safety and about risk.
Exiting the EU: New Partnership — House of Commons, 2017-02-02
Topic: Health
Theresa Anne Villiers (Conservative, Centre-right): I urge the Secretary of State to give priority to the matters in chapter 6 of the White Paper on securing the rights of EU nationals. I have in mind a constituent who is an EU national and who has sadly been receiving cancer treatment for many years. I am anxious to be able to give her certainty as soon as possible that she will continue to have access to the NHS.
Exiting the EU: New Partnership — House of Commons, 2017-02-02
Topic: Health
David Michael Davis (Conservative, Centre-right): That is part of the point of doing this. We are talking about not only residents’ rights, but the right of access to healthcare. That matters both for Europeans in Britain and for Britons abroad. I absolutely agree with my right hon. Friend.
Ukraine — House of Commons, 2022-05-25
Topic: Defense
Geraint Richard Davies (Labour, Centre-left): Given the phenomenal impact on world food supplies, the cost of living crisis here, and the forecasts, which are now increasing, that the global economy will shrink by something like £750 billion thanks to this war, why is more not being done to invest in armoury and defence weaponry to basically kick Russia out of Ukraine? I understand that something like £7 billion of military aid has been provided. Is that enough? Should the world not be doing more, in its own self-interest?
Public Administration and Constitutional Affairs Committee — House of Commons, 2017-02-02
Topic: Health
Edward Glyn Davies (Conservative, Centre-right): I, too, greatly welcome this report, as do my constituents. That may seem surprising to some of my colleagues, as, of course, my constituency is in Wales, but all my constituents use hospitals in England for elective care and specialist care, so this is as important to the people of Wales as it is to the people of England. I have also been involved in many of the complaints. Does the Chair of the Committee acknowledge that, in the debates that he has had and in any follow-up debate that he might have, the position of Welsh constituents is key, because, although they are in another Administration as far as health is concerned, they depend on hospitals in England for treatment?
Public Administration and Constitutional Affairs Committee — House of Commons, 2017-02-02
Topic: Health
Bernard Christison Jenkin (Conservative, Centre-right): I am most grateful to my Welsh hon. Friend for his question. It gives me an opportunity to highlight not only my agreement with the point that he makes, but that this is just about healthcare safety investigations in England. By pursuing this policy to set up HSIB, the Government have embarked on a very, very major and significant reform, which the health services in Scotland, Wales and Northern Ireland are certainly watching. I can assure my hon. Friend that they are being watched all over the world. Different countries in different jurisdictions have tried using various bodies to deal with this question. I do not think that any country before England has embarked on a reform of this scale and nature that has the capacity to transform safety investigation in a health system. I very much hope that Wales, Scotland and Northern Ireland will either set up their own equivalent of HSIB, or employ HSIB as the pinnacle of their investigation system as well. This matter is not something that necessarily needs to be devolved any more than the Air Accidents Investigation Branch of the Department for Transport.
Public Administration and Constitutional Affairs Committee — House of Commons, 2017-02-02
Topic: Health
Peter James Bottomley (Conservative, Centre-right): Does the Chairman agree that each of us receives from our constituents many more golden letters about their treatment in the health service than letters of complaint? When there are complaints or questions, openness and responsiveness matter most, and most of our constituents are satisfied with that. HSIB will be for the pinnacle of the hardest cases, but most cases should be resolved locally by the GPs or the hospitals.
Public Administration and Constitutional Affairs Committee — House of Commons, 2017-02-02
Topic: Health
Bernard Christison Jenkin (Conservative, Centre-right): I certainly agree that the vast majority of our constituents who experience the care of hospitals or GP practices are extremely grateful for the quality of care that they receive. However, we cannot underestimate how corrosive the blame culture has been throughout our health system. Crises such as those at Mid Staffordshire and at the Morecambe Bay maternity unit arise from the defensive culture that exists in the NHS. If we are to change that into a much more open and collaborative system of learning from mistakes, we need HSIB to set the tone throughout the entire organisation. It is not just about dealing with a few complaints, but about setting a whole new standard for a whole new profession in the NHS about how complaints and clinical incidents are investigated. I am most grateful to have the opportunity to present this report.
Public Administration and Constitutional Affairs Committee — House of Commons, 2017-02-02
Topic: Health
Philip Martin Dunne (Conservative, Centre-right): I wish to add my thanks to my hon. Friend and members of the Committee for their considered report. He has succinctly described to the House what more needs to be done systematically to transform the way in which the NHS learns from errors to improve patient safety. We support the main thrust of the Committee’s recommendations and will offer a detailed response to the report in due course. Like the Committee, we put this matter right at the top of our agenda to change the culture within the NHS, of which he has spoken so eloquently today. We are committed to making our hospitals and GP surgeries the safest in the world, supported by the NHS as the world’s largest learning organisation. The only way in which we will achieve that is through a learning rather than a blame culture characterised by openness, honesty and candour; listening to patients, families and staff; finding and facing the truth; and learning from errors and failures in care As my hon. Friend has indicated, the Government have accepted the recommendation of PACAC’s predecessor Committee to establish an independent healthcare safety investigation service. The Healthcare Safety Investigation Branch will be up and running from April. I join him in welcoming the appointment of Keith Conradi, the former chief inspector of the Air Accidents Investigation Branch, who has a strong track record of delivering high-quality investigations in aviation The hon. Gentleman’s Committee has again called for HSIB to be statutorily independent, and we agree that it should be as independent as possible if it is to discharge its functions fully and effectively, and we would not rule out the option of legislation. His Committee has also raised, in this week’s report, various suggestions for HSIB and its potential role in setting standards. We will be responding to that formally in due course We are committed to ensuring that the NHS becomes an organisation that learns from its mistakes. In response to the Care Quality Commission’s report, "Learning, Accountability and Candour", from April this year all NHS trusts will be required to publish how many deaths they could have avoided had care been better, along with the lessons that they have learned Before I pose my question, I should like to thank the Committee for its response to the Government’s recent consultation, "Providing a Safe Space in Healthcare Safety Investigations", and we will be responding to it shortly Improvements in safety, incident handling and learning in the NHS will not happen overnight, but does my hon. Friend agree that the shared programme of work demonstrates a commitment, across the care system, to improve the way in which all serious patient safety incidents are viewed and treated, and is that not a crucial foundation for lasting change?
Ukraine — House of Commons, 2022-05-25
Topic: Defense
Wayne David (Labour, Centre-left): One thing that has become increasingly clear is that the war in Ukraine will not be a short conflict; it will go on for some time. It is important therefore that we maintain our solidarity and our practical support. That means continuing the supply of armaments, which prompts the question: have we sufficient resources of our own to maintain that constant flow?
Armed Forces Covenant — House of Commons, 2017-02-02
Topic: Defense
Anne-Marie Belinda Trevelyan (Conservative, Centre-right): I thank the Minister very much for that intervention. I hope that we can look at that in detail The hierarchical and command-based rules that are needed for military discipline in war should never create a barrier whereby military personnel and their families are not free to raise concerns about day-to-day issues that affect them. Those issues, to name but a few, might be: family housing matters, which are subject to the MOD’s oversight; school matters, which come under the purview of the Department for Education; or health matters, which are the responsibility of the Department of Health.